Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ:CDXC) reported fiscal year 2021 net sales of $67.4 million, a 14% increase from 2020, driven by Tru Niagen® sales of $56.7 million. Fourth quarter sales reached $17.8 million, up 15%, while gross margins improved to 61.5%. Despite a net loss of $5.3 million for Q4, the company experienced reduced losses year-over-year. Looking ahead, ChromaDex expects 15-20% revenue growth in 2022, supported by e-commerce and strategic partnerships. The company plans to focus on brand awareness and R&D.
ChromaDex Corp. (NASDAQ:CDXC) announced positive results from a Phase I clinical trial investigating its proprietary ingredient Niagen® in Parkinson’s disease (PD) patients. The study demonstrated a significant increase in cerebral NAD levels and a reduction in inflammatory cytokines. The trial involved 30 newly diagnosed patients, with results indicating improved brain metabolism and mild clinical enhancements. A Phase II study is ongoing, aiming to evaluate NR supplementation in 400 PD patients, thus positioning NR as a potential neuroprotective therapy.
ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on March 9, 2022, at 4:30 p.m. ET, to discuss its Q4 2021 financial results, reported after market hours. The call will also cover general business updates. Interested participants are encouraged to dial in 10 minutes prior to the start time. The conference call can be accessed here and will be available for replay until March 16, 2022.
ChromaDex Corp. (NASDAQ: CDXC) announced the granting of a continuation patent for its key ingredient, Niagen®, a form of nicotinamide riboside (NR). This patent enhances its intellectual property protection, bringing the total to over 40 patents related to NR and NAD precursors. The new U.S. Patent No. 11,242,364, which expires on Nov. 10, 2037, secures the manufacturing processes of NR and its salt forms, supporting potential future innovations. CEO Rob Fried emphasizes the significance of NR in healthy aging.
Summary not available.
ChromaDex Corp. (NASDAQ:CDXC) announced results from its 18th clinical trial on Niagen®, a nicotinamide riboside ingredient. Published in the Journal of Clinical Investigation, the study demonstrated that NR supplementation reduces Type-I interferon signaling, which is significant for immune response, particularly in young individuals and lupus patients. Conducted with 35 volunteers, the pilot study supports the potential anti-inflammatory properties of NR, with researchers advocating for further studies on its effects in autoimmune disorders.
ChromaDex (NASDAQ:CDXC) has entered into a supply agreement with Designs for Health, a U.S.-based dietary supplement manufacturer. The partnership will incorporate Niagen®, a patented form of nicotinamide riboside, into multi-ingredient products exclusively for healthcare practitioners.
This collaboration aims to enhance the distribution of Niagen® in the U.S., Canada, and Australia, leveraging Designs for Health's established network. Both companies emphasize the importance of providing science-backed health solutions to improve consumer education regarding NAD+.
ChromaDex Corp. (NASDAQ:CDXC) reported third quarter 2021 net sales of $17.3 million, a 22% increase year-over-year. Notably, Tru Niagen® sales reached $14.8 million, up 24%. Despite improved gross margin at 61.1%, the company incurred a net loss of $(8.9) million, deteriorating from $(4.2) million last year. Operating expenses rose to $19.4 million, due in part to increased legal costs. Looking ahead, ChromaDex anticipates continued revenue growth driven by its e-commerce strategy and strategic partnerships, while investing in brand awareness and R&D.
ChromaDex announced promising results from a clinical study on nicotinamide riboside (NR) for patients with ataxia-telangiectasia (AT), a rare neurodegenerative disorder. Conducted by Radboud University Medical Center, the study demonstrated that NR improved ataxia scores and increased immunoglobulin levels in 24 participants, including 17 children. Patients received 25mg/kg of NR daily for four months. Though results are encouraging, further research is needed to confirm the therapeutic potential of NR for AT.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 3, 2021, at 4:30 p.m. ET to discuss its third quarter financial results for the period ending September 30, 2021. The results will be disclosed in a press release after market close on the same day. Interested participants should call in 10 minutes prior to the call, with details provided. A replay will be available from 7:30 p.m. ET on November 3 until 11:59 p.m. ET on November 10. ChromaDex focuses on healthy aging, pioneering research around NAD+ and its products.